The interplay between non-alcoholic fatty liver disease and innate immunity in hepatitis B virus patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Fayed Attia Koutb Megahed ◽  
Xiaoling Zhou ◽  
Pingnan Sun ◽  
Marwa Mohamed Elmaghrabi
Keyword(s):  
Innate Immunity ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Fatty Liver ◽  
Chronic Hepatitis B ◽  
Fatty Liver Disease ◽  
Innate Immune ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is the most epidemic liver disorder worldwide as a result of rapid lifestyle transformation over the past few decades and is expected to elevate in the next few years as well as it is ranging from plain hepatic steatosis via non-alcoholic steatohepatitis (NASH) to liver cirrhosis and hepatocellular carcinoma (HCC). Main text NAFLD can also stimulate the diseases progression as diabetes and cardiovascular. Therefore, understanding the NAFLD pathogenesis is of vital clinical interest additionally is a crucial for disease treatment and prevention. After analyzing NAFLD and liver diseases prevalence, it has been a belief regarding the interaction between NAFLD and chronic hepatitis B (CHB). Conclusion The liver is an essential innate immune organ with large numbers of innate immune cells that contribute in NAFLD pathogenesis, additionally play the influential role that control NAFLD progression in the hepatitis B patients. Here, we summarized the recent advances in understanding and managing the NAFLD patients with chronic hepatitis B infection and interplay with innate immunity.

Impact of non-alcoholic fatty liver disease on chronic hepatitis B

2007 ◽  
Vol 27 (5) ◽  
pp. 607-611 ◽  
Author(s):  
Silvia Bondini ◽  
Jillian Kallman ◽  
Angela Wheeler ◽  
Shivaani Prakash ◽  
Terry Gramlich ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Fatty Liver ◽  
Chronic Hepatitis B ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Chronic hepatitis B and non‐alcoholic fatty liver disease: Conspirators or competitors?

2020 ◽  
Vol 40 (3) ◽  
pp. 496-508
Author(s):  
Jianbin Zhang ◽  
Shuangzhe Lin ◽  
Daixi Jiang ◽  
Mengting Li ◽  
Yuanwen Chen ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Fatty Liver ◽  
Chronic Hepatitis B ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals Non-alcoholic fatty liver disease in patients with chronic viral hepatitis

2014 ◽  
Vol 95 (1) ◽  
pp. 35-41 ◽  
Author(s):  
L I Tkachenko ◽  
V V Maleev
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis B ◽  
Fatty Liver ◽  
Chronic Hepatitis B ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Group I ◽  
Liver Biopsies ◽  
Alcoholic Fatty Liver Disease

Aim. To estimate the prevalence of non-acloholic fatty liver disease in patients with chronic hepatitis B, and the association of non-acloholic fatty liver disease with the biochemical, virological and metabolic faсtors. Methods. 53 patients with chronic hepatitis B observed in the regional hospital of infective diseases, Stavropol, at 2008-2012, were included. Patients were distributed to 2 groups according to the results of liver biopsies: group I - patients with hepatosteatosis (5%) and group II - no signs of steatosis (≤5%). Anthropometric, histological, biochemical, virological, and metabolic determinants were compared. Results. Of 53 patients, 18 (34%) liver biopsies had signs of steatosis. Patients with steatosis (group I), compared with group II, were older (43±13 vs 34.5±10.9 years, р=0.015), had higher body mass index (30±5.3 vs 22.9±4.3 kg/m 2, р=0.015), higher level of triglycerides (1.6±0.8 vs 1.06±0.7 mmol/l, р=0.014), higher level of cholesterol (5.6±0.7 vs 4.97±0.9 mmol/l, р=0.012), and higher serum insulin (13±7.9 vs 8.2±3 mkME/l, р=0.002) and leptin levels (16.2±15.6 vs 6.5±5.2 ng/ml, р=0.001). The values of HOMA (Homeostasis Model Assessment) and QUICKI (quantitative insulin sensitivity check index) indices corresponded to insulin resistance (НОМА 2.9±1.8 and 1.9±0.8, р=0.007; QUICKI 0.33±0.02 and 0.35±0.03, р=0.014). There were no differences in histological activity scores by Knodell and fibrosis scores by METAVIR scale between the groups. No reliable differences in virological parameters (viral load and HBeAg status) were obtained. Conclusion. Non-alcoholic fatty liver disease is observed in one-third of patients with hepatitis B and is associated with host metabolic factors, which correspond to the parameters of metabolic syndrome.

Sign in / Sign up

Export Citation Format

Share Document